ING4 inhibitors refer to a class of chemical compounds that target the inhibitor of growth 4 (ING4) protein, a member of the ING family of tumor suppressors. ING4, also known as inhibitor of growth 4, is a crucial modulator of various cellular processes, including chromatin remodeling, transcriptional regulation, and DNA repair. The ING family proteins are distinguished by their ability to interact with histone acetyltransferase and histone deacetylase complexes, contributing to the modulation of gene expression and epigenetic regulation. ING4 specifically acts as a bridge between chromatin and these enzyme complexes, exerting its functions through its conserved plant homeodomain (PHD) finger and nuclear localization signals. ING4 inhibitors are designed to interfere with the interactions between ING4 and its associated complexes, ultimately impacting its role in epigenetic regulation and gene expression modulation.
These inhibitors typically target the binding pocket of the PHD finger domain, disrupting its ability to interact with histones and other protein partners. By doing so, they can potentially alter the accessibility of DNA to transcriptional machinery, leading to downstream effects on cellular processes such as cell cycle progression, apoptosis, and DNA damage repair. Research into ING4 inhibitors is part of the broader effort to understand the intricate networks of epigenetic regulation and their influence on cellular behavior. These compounds serve as valuable tools in dissecting the functions of ING4 and its associated pathways, providing insights into potential mechanisms for controlling cellular processes through epigenetic modulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. Blocks ATP binding, preventing phosphorylation cascade. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor. Binds to ATP pocket, inhibiting receptor autophosphorylation and downstream signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor blocking RAF, VEGFR, PDGFR, and others. Disrupts tumor cell proliferation and angiogenesis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dual BCR-ABL and SRC family kinase inhibitor. Binds to active conformation, inhibiting proliferation and survival. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor binding to FKBP12. Complex inhibits mTORC1, suppressing cell growth, proliferation, and autophagy. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor similar to rapamycin. Slows cell cycle progression and angiogenesis by targeting mTORC1 complex. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Bruton's tyrosine kinase (BTK) inhibitor. Blocks B-cell receptor signaling, leading to apoptosis in B-cell malignancies. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor disrupting mitochondrial apoptotic pathway. Induces apoptosis in B-cell lymphomas and leukemias. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK and RET kinase inhibitor. Blocks aberrant signaling in ALK-positive non-small cell lung cancer (NSCLC). | ||||||